Transdermal Scopolamine Patch Without Release Membrane
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current transdermal scopolamine delivery systems are complex and costly due to their multi-layered structure, prone to cold flow leading to contamination, and require thermodynamic oversaturation which can cause crystal formation, and they pose a risk of cross-contamination due to full active ingredient loading without a release-determining membrane.
Innovation Solution
A transdermal therapeutic system comprising a skin contact layer, a reservoir layer with scopolamine as the free base, and an impermeable backing layer, where scopolamine is dissolved in the skin contact layer and partially suspended in the reservoir layer, utilizing amine-resistant silicone adhesive polymers and permeation enhancers to achieve a high initial flux and sustained release without a release-determining membrane.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a rate-controlling membrane is used in transdermal scopolamine patches, then the release rate of scopolamine is controlled, but the device complexity and manufacturing cost increase
Solution Approach 1:
The invention removes the rate-controlling membrane from the transdermal patch structure, extracting this component entirely. Instead, the adhesive layer itself is formulated to provide the rate-controlling function through its composition and properties, thereby simplifying the overall device structure while maintaining controlled release capability
Solution Approach 2:
The adhesive layer is given multiple functions: it serves both as the bonding agent to attach the patch to the skin and as the rate-controlling matrix for drug release. This multi-functionality eliminates the need for a separate rate-controlling membrane layer, reducing device complexity while maintaining therapeutic control
2Quantity of substance
If the system is fully loaded with active ingredient to provide sufficient quantities, then therapeutic effectiveness is improved, but cross-contamination risk increases during application
Solution Approach 1:
The scopolamine is not uniformly distributed throughout the entire patch structure, but is specifically localized within the adhesive layer that contacts the skin. This local concentration ensures therapeutic effectiveness at the application site while minimizing exposure to other areas during handling and application
Solution Approach 2:
The adhesive layer acts as an intermediary that contains and controls the active ingredient. It serves as a barrier that prevents direct contact with bulk scopolamine during application, thereby reducing cross-contamination risk while still providing sufficient drug delivery to the skin
3Speed
If thermodynamic oversaturation is used to provide sufficient active ingredient, then initial flux is improved, but crystal formation occurs during storage
Solution Approach 1:
The invention changes the physical state parameters of the scopolamine in the adhesive layer, maintaining it in a dissolved or dispersed state rather than a supersaturated state. By adjusting the adhesive composition and scopolamine concentration parameters, the system achieves high initial flux without the instability and crystal formation associated with thermodynamic oversaturation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This system provides a simple, cost-effective, and safe delivery of scopolamine with reduced risk of cross-contamination, achieving a high initial flux and sustained therapeutic levels over 72 hours, ensuring bioequivalence to existing systems while preventing unwanted side effects.
Implementation Method 1
the active ingredient is dissolved in the active ingredient-containing skin contact layer
Implementation Method 2
provides a high initial flux and sustained release
Implementation Method 3
the active ingredient is partially suspended in the active ingredient-containing reservoir layer
Implementation Method 4
utilizing amine-resistant silicone adhesive polymers and permeation enhancers to achieve a high initial flux
Data Source
Figure 1~2
AI summary
The invention relates to a transdermal therapeutic system without a release-determining membrane for dispensing scopolamine, comprising a skin contact layer, an active substance-containing reservoir layer, an active substance-impermeable back layer, and optionally a protective layer which can be detached from the skin contact layer, wherein the skin contact layer is in direct contact with the active substance-containing reservoir layer. The skin layer or the skin layer and the reservoir layer can be equipped with adhesive strength-increasing additives, for example silicone oils. Furthermore, the system can be equipped with an active substance-free over-patch in order to ensure a sufficient adhesion onto the skin over the application duration. In comparison to comparable systems with a release-determining membrane, a similar bioavailability of the active substance was achieved such that the systems are bioequivalent to the membrane-containing systems. The invention additionally relates to the aforementioned transdermal therapeutic systems for use in the treatment of motion sickness and/or post-operative nausea as well as to methods for producing same.